<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01516437</url>
  </required_header>
  <id_info>
    <org_study_id>116021</org_study_id>
    <nct_id>NCT01516437</nct_id>
  </id_info>
  <brief_title>A Study to Assess Immunity to Specific Microbial Antigens in Healthy Smokers and Non-smokers and in Subjects With Stable COPD</brief_title>
  <official_title>A Study to Assess Immunity to Specific Microbial Antigens in Healthy Smokers and Non-smokers and in Subjects With Stable Chronic Obstructive Pulmonary Disease (COPD) Aged Between 45-75 Years</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <brief_summary>
    <textblock>
      The present study aims to assess the natural immunity to specific microbial antigens in&#xD;
      healthy subjects and in subjects with stable COPD aged between 45-75 years.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 1, 2012</start_date>
  <completion_date type="Actual">December 20, 2012</completion_date>
  <primary_completion_date type="Actual">June 28, 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Anti-protein D Antibody Concentrations</measure>
    <time_frame>At Day 0</time_frame>
    <description>Concentrations are presented as geometric mean concentrations (GMCs), expressed in enzyme-linked immunosorbent assay (ELISA) units per millilitre (EU/mL)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Anti-protein D Antibody Concentrations</measure>
    <time_frame>At Month 6</time_frame>
    <description>Concentrations are presented as geometric mean concentrations (GMCs), expressed in ELISA units per millilitre (EU/mL)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Anti-Pneumococcal Histidine Triad D Antibody Concentrations</measure>
    <time_frame>At Day 0</time_frame>
    <description>Concentrations are presented as geometric mean concentrations (GMCs), expressed in ELISA units per millilitre (EU/mL)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Anti-Pneumococcal Histidine Triad D Antibody Concentrations</measure>
    <time_frame>At Month 6</time_frame>
    <description>Concentrations are presented as geometric mean concentrations (GMCs), expressed in ELISA units per millilitre (EU/mL)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Anti-pneumolysin Antibody Concentrations</measure>
    <time_frame>At Day 0</time_frame>
    <description>The analysis was performed on the According-to-Protocol cohort at Day 0, which included all evaluable subjects for whom at least one assay results was available for the blood samples collected at Day 0.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Anti-pneumolysin Antibody Concentrations</measure>
    <time_frame>At Month 6</time_frame>
    <description>Concentrations are presented as geometric mean concentrations (GMCs), expressed in ELISA units per millilitre (EU/mL)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Concentrations for Serum Protein-D Enzymatic Inhibition</measure>
    <time_frame>At Day 0</time_frame>
    <description>Concentrations are presented as geometric mean concentrations (GMCs). The reference seropositivity cut-off value was ≥ 17.8%.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Concentrations for Serum Protein-D Enzymatic Inhibition</measure>
    <time_frame>At Month 6</time_frame>
    <description>Concentrations are presented as geometric mean concentrations (GMCs). The reference seropositivity cut-off value was ≥ 17.8%.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Subjects With PD Enzymatic Inhibition Concentration Greater Than or Equal to (≥) 17.8%</measure>
    <time_frame>At Day 0</time_frame>
    <description>Concentrations were expressed as geometric mean concentrations (GMCs)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Subjects With PD Enzymatic Inhibition Concentration Greater Than or Equal to (≥) 17.8%</measure>
    <time_frame>At Month 6</time_frame>
    <description>Concentrations were expressed as geometric mean concentrations (GMCs)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Frequency of Specific Cluster of Differentiation 4+ (CD4+) T Cells Expressing at Least 2 Markers Among CD 40 Ligand (CD40L), Interleukin 2 (IL-2), Tumor Necrosis Factor-α (TNF-α), Interferon-γ (IFN-γ), IL-13 and IL-17 Upon in Vitro Stimulation</measure>
    <time_frame>At Day 0</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of Specific Cluster of Differentiation 8+ (CD8+) T Cells Expressing at Least 2 Markers Among CD 40 Ligand (CD40L), Interleukin 2 (IL-2), Tumor Necrosis Factor-α (TNF-α), Interferon-γ (IFN-γ), IL-13 and IL-17 Upon in Vitro Stimulation</measure>
    <time_frame>At Day 0</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Positive Sputum - Culture Testing Results</measure>
    <time_frame>At Day 0</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Positive Nasopharyngeal Swab - Culture Testing Results</measure>
    <time_frame>At Day 0</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Positive Oropharyngeal Swab - Culture Testing Results</measure>
    <time_frame>At Day 0</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">73</enrollment>
  <condition>Respiratory Disorders</condition>
  <arm_group>
    <arm_group_label>HNS Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy non-smokers aged between 45-75 years</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HS Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy smokers aged between 45-75 years</description>
  </arm_group>
  <arm_group>
    <arm_group_label>FeCOPD Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>COPD subjects with ≥ two exacerbations within 365 days prior to the screening visit (frequent exacerbators), aged between 45-75 years</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NFeCOPD Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>COPD patients with one exacerbation within 365 days prior to the screening visit (non-frequent exacerbators), aged between 45-75 years</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Blood collection</intervention_name>
    <description>Blood collection at Day 0 (all subjects) and at Month 6 (COPD subjects) for the analysis of serology, cell-mediated immune response.</description>
    <arm_group_label>FeCOPD Group</arm_group_label>
    <arm_group_label>HNS Group</arm_group_label>
    <arm_group_label>HS Group</arm_group_label>
    <arm_group_label>NFeCOPD Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Swab collection</intervention_name>
    <description>Nasopharyngeal and oropharyngeal swabs collection at Day 0 (All subjects) and at exacerbation visits (COPD subjects).</description>
    <arm_group_label>FeCOPD Group</arm_group_label>
    <arm_group_label>HNS Group</arm_group_label>
    <arm_group_label>HS Group</arm_group_label>
    <arm_group_label>NFeCOPD Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Sputum collection</intervention_name>
    <description>Sputum collection at Day 0 and at exacerbation visits (COPD subjects)</description>
    <arm_group_label>FeCOPD Group</arm_group_label>
    <arm_group_label>NFeCOPD Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Healthy subjects (smokers and non-smokers)&#xD;
&#xD;
          -  Subjects who the investigator believes can and will comply with the requirements of&#xD;
             the protocol.&#xD;
&#xD;
          -  A male or female between, and including 45 and 75 years of age at the time of consent.&#xD;
&#xD;
          -  Written informed consent obtained from the subject.&#xD;
&#xD;
          -  Baseline post-bronchodilator Forced Expiratory Volume of air in one second (FEV1) &gt;&#xD;
             85% of predicted normal values and baseline post-bronchodilator FEV1/Forced expiratory&#xD;
             Vital Capacity (FVC) &gt; 70% of predicted normal values.&#xD;
&#xD;
          -  Free of obvious health problems as established by medical history and clinical&#xD;
             examination before entering into the study.&#xD;
&#xD;
          -  Non-smokers: subjects who never smoked OR&#xD;
&#xD;
          -  Smokers: current smoker having a smoking history ≥ 10 pack-years.&#xD;
&#xD;
        COPD subjects (frequent and non-frequent exacerbators)&#xD;
&#xD;
          -  Subjects who the investigator believes can and will comply with the requirements of&#xD;
             the protocol.&#xD;
&#xD;
          -  A male or female between, and including 45 and 75 years of age at the time of consent.&#xD;
&#xD;
          -  Written informed consent obtained from the subject.&#xD;
&#xD;
          -  Baseline post-bronchodilator FEV1 &lt; 80% and &gt;30% of predicted normal values and&#xD;
             baseline post-bronchodilator FEV1/FVC &lt; 70% of predicted normal values.&#xD;
&#xD;
          -  Current or former smoker having a smoking history of ≥ 10 pack-years.&#xD;
&#xD;
          -  Documented history of ≥ one exacerbation within 365 days prior to the screening visit&#xD;
             that required treatment with systemic corticosteroids or resulted in hospitalization.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Healthy subjects (smokers and non-smokers)&#xD;
&#xD;
          -  Use of any investigational or non-registered product within 30 days prior to Screening&#xD;
             Visit or planned use during the study.&#xD;
&#xD;
          -  Concurrently participating in another clinical study in which the subject has been or&#xD;
             will be exposed to an investigational or a non-investigational product.&#xD;
&#xD;
          -  Any known clinically significant anaemia or any other condition as per medical records&#xD;
             that would preclude the drawing of blood as described in the protocol.&#xD;
&#xD;
          -  Receipt of any vaccine within 30 days preceding blood sampling.&#xD;
&#xD;
          -  Previous vaccination with any NTHi vaccine.&#xD;
&#xD;
          -  Chronic administration of immunosuppressants or other immune-modifying drugs within&#xD;
             180 days prior to screening visit. Topical steroids are allowed.&#xD;
&#xD;
          -  Any confirmed or suspected immunosuppressive or immunodeficient condition including&#xD;
             human immunodeficiency virus (HIV) infection, based on medical history and physical&#xD;
             examination.&#xD;
&#xD;
          -  Serious chronic disease including any medically significant chronic pulmonary,&#xD;
             cardiovascular, renal, neurological, psychiatric or metabolic disorder, as determined&#xD;
             by medical history and physical examination.&#xD;
&#xD;
          -  Any known respiratory disorders.&#xD;
&#xD;
          -  Acute disease and/or fever at the time of the Screening Visit or Visit 1, as&#xD;
             applicable&#xD;
&#xD;
          -  Receipt of immunoglobulins and/or any blood products within 90 days prior to Screening&#xD;
             Visit.&#xD;
&#xD;
          -  Receipt of interferon within 90 days prior to Screening Visit.&#xD;
&#xD;
          -  History of malignancy.&#xD;
&#xD;
          -  Subjects with a history of, or current, alcohol or substance abuse.&#xD;
&#xD;
          -  Known history of immune-mediated disorder.&#xD;
&#xD;
          -  Recent use of antibiotics or antiviral drug within 30 days prior to Screening Visit.&#xD;
&#xD;
          -  Pregnant female.&#xD;
&#xD;
          -  Other conditions that the investigator judges may interfere with study findings.&#xD;
&#xD;
        COPD subjects (frequent and non-frequent exacerbators)&#xD;
&#xD;
          -  Use of any investigational or non-registered product within 30 days prior to Screening&#xD;
             Visit or planned use during the study. Use of investigational inhaled long acting&#xD;
             muscarinic antagonists (LAMA), inhaled long acting beta agonists (LABA) or inhaled&#xD;
             corticosteroids is allowed.&#xD;
&#xD;
          -  Concurrently participating in another clinical study in which the subject has been or&#xD;
             will be exposed to an investigational or a non-investigational product. Subjects&#xD;
             participating in clinical studies with investigational inhaled LAMA and/or LABA and/or&#xD;
             inhaled corticosteroids can be enrolled.&#xD;
&#xD;
          -  Any known clinically significant anaemia or any other condition as per medical records&#xD;
             that would preclude the drawing of blood as described in the protocol.&#xD;
&#xD;
          -  Receipt of any vaccine within 30 days preceding blood sampling.&#xD;
&#xD;
          -  Previous vaccination with any NTHi vaccine.&#xD;
&#xD;
          -  Any confirmed or suspected immunosuppressive or immunodeficient condition including&#xD;
             human immunodeficiency virus (HIV) infection, based on medical history and physical&#xD;
             examination.&#xD;
&#xD;
          -  Serious, uncontrolled disease likely to interfere with the study findings.&#xD;
&#xD;
          -  Acute disease and/or fever at the time of the Screening Visit or Visit 1, as&#xD;
             applicable&#xD;
&#xD;
          -  Receipt of immunoglobulins and/or any blood products within 90 days prior to Screening&#xD;
             Visit.&#xD;
&#xD;
          -  Receipt of interferon within 90 days prior to Screening Visit.&#xD;
&#xD;
          -  History of malignancy.&#xD;
&#xD;
          -  Subjects with a history of, or current, alcohol or substance abuse.&#xD;
&#xD;
          -  Known history of immune-mediated disease other than COPD.&#xD;
&#xD;
          -  Recent use of antibiotics or antiviral drug within 30 days prior to Screening Visit.&#xD;
&#xD;
          -  Subject who experienced COPD exacerbation which required antibiotic, systemic&#xD;
             corticosteroid or hospitalisation and which did not resolve at least one month prior&#xD;
             to Screening Visit and at least 30 days following the last dose of oral&#xD;
             corticosteroids.&#xD;
&#xD;
          -  Chronic administration of immunosuppressants or other immune-modifying drugs within&#xD;
             180 days preceding screening visit.&#xD;
&#xD;
          -  Subjects with very severe COPD, GOLD stage IV.&#xD;
&#xD;
          -  Primary diagnosis of asthma.&#xD;
&#xD;
          -  Other respiratory disorders such as sarcoidosis, tuberculosis, lung cancer, lung&#xD;
             fibrosis, cystic fibrosis.&#xD;
&#xD;
          -  A known diagnosis of α-1 antitrypsin deficiency as underlying cause of COPD.&#xD;
&#xD;
          -  History of lung surgery.&#xD;
&#xD;
          -  Pregnant female.&#xD;
&#xD;
          -  Other conditions that the investigator judges may interfere with study findings.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Brussels</city>
        <zip>1000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Liège</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <study_first_submitted>January 19, 2012</study_first_submitted>
  <study_first_submitted_qc>January 19, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 24, 2012</study_first_posted>
  <results_first_submitted>January 10, 2017</results_first_submitted>
  <results_first_submitted_qc>January 16, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">March 7, 2017</results_first_posted>
  <last_update_submitted>April 12, 2017</last_update_submitted>
  <last_update_submitted_qc>April 12, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 17, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chronic Obstructive Pulmonary disease (COPD)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiration Disorders</mesh_term>
    <mesh_term>Respiratory Tract Diseases</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>During the screening the following steps occurred: check for inclusion/exclusion criteria, contraindications/precautions, medical history of the subjects and signing informed consent forms. 3 enrolled subjects did not receive subject allocations, and were excluded from the study prior to start.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>HNS Group</title>
          <description>Healthy non-smokers aged between 45-75 years</description>
        </group>
        <group group_id="P2">
          <title>HS Group</title>
          <description>Healthy smokers aged between 45-75 years</description>
        </group>
        <group group_id="P3">
          <title>FeCOPD Group</title>
          <description>COPD subjects with ≥ two exacerbations within 365 days prior to the screening visit (frequent exacerbators), aged between 45-75 years</description>
        </group>
        <group group_id="P4">
          <title>NFeCOPD Group</title>
          <description>COPD patients with one exacerbation within 365 days prior to the screening visit (non-frequent exacerbators), aged between 45-75 years</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="24"/>
                <participants group_id="P3" count="15"/>
                <participants group_id="P4" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="24"/>
                <participants group_id="P3" count="14"/>
                <participants group_id="P4" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Reason not specified</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>HNS Group</title>
          <description>Healthy non-smokers aged between 45-75 years</description>
        </group>
        <group group_id="B2">
          <title>HS Group</title>
          <description>Healthy smokers aged between 45-75 years</description>
        </group>
        <group group_id="B3">
          <title>FeCOPD Group</title>
          <description>COPD subjects with ≥ two exacerbations within 365 days prior to the screening visit (frequent exacerbators), aged between 45-75 years</description>
        </group>
        <group group_id="B4">
          <title>NFeCOPD Group</title>
          <description>COPD patients with one exacerbation within 365 days prior to the screening visit (non-frequent exacerbators), aged between 45-75 years</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="24"/>
            <count group_id="B2" value="24"/>
            <count group_id="B3" value="15"/>
            <count group_id="B4" value="7"/>
            <count group_id="B5" value="70"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60" spread="10.10"/>
                    <measurement group_id="B2" value="57.8" spread="8.45"/>
                    <measurement group_id="B3" value="64.1" spread="7.39"/>
                    <measurement group_id="B4" value="61.4" spread="6.75"/>
                    <measurement group_id="B5" value="60.26" spread="8.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="33"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Anti-protein D Antibody Concentrations</title>
        <description>Concentrations are presented as geometric mean concentrations (GMCs), expressed in enzyme-linked immunosorbent assay (ELISA) units per millilitre (EU/mL)</description>
        <time_frame>At Day 0</time_frame>
        <population>The analysis was performed on the According-to-Protocol cohort at Day 0, which included all evaluable subjects for whom at least one assay results was available for the blood samples collected at Day 0.</population>
        <group_list>
          <group group_id="O1">
            <title>HNS Group</title>
            <description>Healthy non-smokers aged between 45-75 years</description>
          </group>
          <group group_id="O2">
            <title>HS Group</title>
            <description>Healthy smokers aged between 45-75 years</description>
          </group>
          <group group_id="O3">
            <title>FeCOPD Group</title>
            <description>COPD subjects with ≥ two exacerbations within 365 days prior to the screening visit (frequent exacerbators), aged between 45-75 years</description>
          </group>
          <group group_id="O4">
            <title>NFeCOPD Group</title>
            <description>COPD patients with one exacerbation within 365 days prior to the screening visit (non-frequent exacerbators), aged between 45-75 years</description>
          </group>
        </group_list>
        <measure>
          <title>Anti-protein D Antibody Concentrations</title>
          <description>Concentrations are presented as geometric mean concentrations (GMCs), expressed in enzyme-linked immunosorbent assay (ELISA) units per millilitre (EU/mL)</description>
          <population>The analysis was performed on the According-to-Protocol cohort at Day 0, which included all evaluable subjects for whom at least one assay results was available for the blood samples collected at Day 0.</population>
          <units>EU/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="15"/>
                <count group_id="O4" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79.5" lower_limit="50.2" upper_limit="126.0"/>
                    <measurement group_id="O2" value="66.9" lower_limit="53.1" upper_limit="84.3"/>
                    <measurement group_id="O3" value="61.7" lower_limit="48.3" upper_limit="78.7"/>
                    <measurement group_id="O4" value="72.8" lower_limit="40.1" upper_limit="132.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Anti-protein D Antibody Concentrations</title>
        <description>Concentrations are presented as geometric mean concentrations (GMCs), expressed in ELISA units per millilitre (EU/mL)</description>
        <time_frame>At Month 6</time_frame>
        <population>The analysis was performed on the According-to-Protocol cohort at Month 6, which included all evaluable subjects for whom at least one assay results was available for the blood samples collected at Month 6.</population>
        <group_list>
          <group group_id="O1">
            <title>FeCOPD Group</title>
            <description>COPD subjects with ≥ two exacerbations within 365 days prior to the screening visit (frequent exacerbators), aged between 45-75 years</description>
          </group>
          <group group_id="O2">
            <title>NFeCOPD Group</title>
            <description>COPD patients with one exacerbation within 365 days prior to the screening visit (non-frequent exacerbators), aged between 45-75 years</description>
          </group>
        </group_list>
        <measure>
          <title>Anti-protein D Antibody Concentrations</title>
          <description>Concentrations are presented as geometric mean concentrations (GMCs), expressed in ELISA units per millilitre (EU/mL)</description>
          <population>The analysis was performed on the According-to-Protocol cohort at Month 6, which included all evaluable subjects for whom at least one assay results was available for the blood samples collected at Month 6.</population>
          <units>EU/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.6" lower_limit="50.2" upper_limit="93.9"/>
                    <measurement group_id="O2" value="61.0" lower_limit="36.6" upper_limit="101.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Anti-Pneumococcal Histidine Triad D Antibody Concentrations</title>
        <description>Concentrations are presented as geometric mean concentrations (GMCs), expressed in ELISA units per millilitre (EU/mL)</description>
        <time_frame>At Day 0</time_frame>
        <population>The analysis was performed on the According-to-Protocol cohort at Day 0, which included all evaluable subjects for whom at least one assay results was available for the blood samples collected at Day 0.</population>
        <group_list>
          <group group_id="O1">
            <title>HNS Group</title>
            <description>Healthy non-smokers aged between 45-75 years</description>
          </group>
          <group group_id="O2">
            <title>HS Group</title>
            <description>Healthy smokers aged between 45-75 years</description>
          </group>
          <group group_id="O3">
            <title>FeCOPD Group</title>
            <description>COPD subjects with ≥ two exacerbations within 365 days prior to the screening visit (frequent exacerbators), aged between 45-75 years</description>
          </group>
          <group group_id="O4">
            <title>NFeCOPD Group</title>
            <description>COPD patients with one exacerbation within 365 days prior to the screening visit (non-frequent exacerbators), aged between 45-75 years</description>
          </group>
        </group_list>
        <measure>
          <title>Anti-Pneumococcal Histidine Triad D Antibody Concentrations</title>
          <description>Concentrations are presented as geometric mean concentrations (GMCs), expressed in ELISA units per millilitre (EU/mL)</description>
          <population>The analysis was performed on the According-to-Protocol cohort at Day 0, which included all evaluable subjects for whom at least one assay results was available for the blood samples collected at Day 0.</population>
          <units>EU/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="15"/>
                <count group_id="O4" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3786.7" lower_limit="2748.3" upper_limit="5217.5"/>
                    <measurement group_id="O2" value="3400.7" lower_limit="2445.3" upper_limit="4729.4"/>
                    <measurement group_id="O3" value="3323.9" lower_limit="2128.8" upper_limit="5190.1"/>
                    <measurement group_id="O4" value="2563.9" lower_limit="840.5" upper_limit="7821.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Anti-Pneumococcal Histidine Triad D Antibody Concentrations</title>
        <description>Concentrations are presented as geometric mean concentrations (GMCs), expressed in ELISA units per millilitre (EU/mL)</description>
        <time_frame>At Month 6</time_frame>
        <population>The analysis was performed on the According-to-Protocol cohort at Month 6, which included all evaluable subjects for whom at least one assay results was available for the blood samples collected at Month 6.</population>
        <group_list>
          <group group_id="O1">
            <title>FeCOPD Group</title>
            <description>COPD subjects with ≥ two exacerbations within 365 days prior to the screening visit (frequent exacerbators), aged between 45-75 years</description>
          </group>
          <group group_id="O2">
            <title>NFeCOPD Group</title>
            <description>COPD patients with one exacerbation within 365 days prior to the screening visit (non-frequent exacerbators), aged between 45-75 years</description>
          </group>
        </group_list>
        <measure>
          <title>Anti-Pneumococcal Histidine Triad D Antibody Concentrations</title>
          <description>Concentrations are presented as geometric mean concentrations (GMCs), expressed in ELISA units per millilitre (EU/mL)</description>
          <population>The analysis was performed on the According-to-Protocol cohort at Month 6, which included all evaluable subjects for whom at least one assay results was available for the blood samples collected at Month 6.</population>
          <units>EU/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2521.5" lower_limit="1598.6" upper_limit="3977.4"/>
                    <measurement group_id="O2" value="2160.1" lower_limit="863.2" upper_limit="5405.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Anti-pneumolysin Antibody Concentrations</title>
        <description>The analysis was performed on the According-to-Protocol cohort at Day 0, which included all evaluable subjects for whom at least one assay results was available for the blood samples collected at Day 0.</description>
        <time_frame>At Day 0</time_frame>
        <population>The analysis was performed on the According-to-Protocol cohort at Day 0, which included all evaluable subjects for whom at least one assay results was available for the blood samples collected at Day 0.</population>
        <group_list>
          <group group_id="O1">
            <title>HNS Group</title>
            <description>Healthy non-smokers aged between 45-75 years</description>
          </group>
          <group group_id="O2">
            <title>HS Group</title>
            <description>Healthy smokers aged between 45-75 years</description>
          </group>
          <group group_id="O3">
            <title>FeCOPD Group</title>
            <description>COPD subjects with ≥ two exacerbations within 365 days prior to the screening visit (frequent exacerbators), aged between 45-75 years</description>
          </group>
          <group group_id="O4">
            <title>NFeCOPD Group</title>
            <description>COPD patients with one exacerbation within 365 days prior to the screening visit (non-frequent exacerbators), aged between 45-75 years</description>
          </group>
        </group_list>
        <measure>
          <title>Anti-pneumolysin Antibody Concentrations</title>
          <description>The analysis was performed on the According-to-Protocol cohort at Day 0, which included all evaluable subjects for whom at least one assay results was available for the blood samples collected at Day 0.</description>
          <population>The analysis was performed on the According-to-Protocol cohort at Day 0, which included all evaluable subjects for whom at least one assay results was available for the blood samples collected at Day 0.</population>
          <units>EU/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="15"/>
                <count group_id="O4" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3870.5" lower_limit="2607.0" upper_limit="5746.3"/>
                    <measurement group_id="O2" value="3116.7" lower_limit="2097.3" upper_limit="4631.8"/>
                    <measurement group_id="O3" value="2804.5" lower_limit="1831.8" upper_limit="4293.7"/>
                    <measurement group_id="O4" value="3898.7" lower_limit="1437.4" upper_limit="10574.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Anti-pneumolysin Antibody Concentrations</title>
        <description>Concentrations are presented as geometric mean concentrations (GMCs), expressed in ELISA units per millilitre (EU/mL)</description>
        <time_frame>At Month 6</time_frame>
        <population>The analysis was performed on the According-to-Protocol cohort at Month 6, which included all evaluable subjects for whom at least one assay results was available for the blood samples collected at Month 6.</population>
        <group_list>
          <group group_id="O1">
            <title>FeCOPD Group</title>
            <description>COPD subjects with ≥ two exacerbations within 365 days prior to the screening visit (frequent exacerbators), aged between 45-75 years</description>
          </group>
          <group group_id="O2">
            <title>NFeCOPD Group</title>
            <description>COPD patients with one exacerbation within 365 days prior to the screening visit (non-frequent exacerbators), aged between 45-75 years</description>
          </group>
        </group_list>
        <measure>
          <title>Anti-pneumolysin Antibody Concentrations</title>
          <description>Concentrations are presented as geometric mean concentrations (GMCs), expressed in ELISA units per millilitre (EU/mL)</description>
          <population>The analysis was performed on the According-to-Protocol cohort at Month 6, which included all evaluable subjects for whom at least one assay results was available for the blood samples collected at Month 6.</population>
          <units>EU/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2275.6" lower_limit="1344.0" upper_limit="3853.0"/>
                    <measurement group_id="O2" value="3222.3" lower_limit="1416.5" upper_limit="7330.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Concentrations for Serum Protein-D Enzymatic Inhibition</title>
        <description>Concentrations are presented as geometric mean concentrations (GMCs). The reference seropositivity cut-off value was ≥ 17.8%.</description>
        <time_frame>At Day 0</time_frame>
        <population>The analysis was performed on the According-to-Protocol cohort at Day 0, which included all evaluable subjects for whom at least one assay results was available for the blood samples collected at Day 0.</population>
        <group_list>
          <group group_id="O1">
            <title>HNS Group</title>
            <description>Healthy non-smokers aged between 45-75 years</description>
          </group>
          <group group_id="O2">
            <title>HS Group</title>
            <description>Healthy smokers aged between 45-75 years</description>
          </group>
          <group group_id="O3">
            <title>FeCOPD Group</title>
            <description>COPD subjects with ≥ two exacerbations within 365 days prior to the screening visit (frequent exacerbators), aged between 45-75 years</description>
          </group>
          <group group_id="O4">
            <title>NFeCOPD Group</title>
            <description>COPD patients with one exacerbation within 365 days prior to the screening visit (non-frequent exacerbators), aged between 45-75 years</description>
          </group>
        </group_list>
        <measure>
          <title>Concentrations for Serum Protein-D Enzymatic Inhibition</title>
          <description>Concentrations are presented as geometric mean concentrations (GMCs). The reference seropositivity cut-off value was ≥ 17.8%.</description>
          <population>The analysis was performed on the According-to-Protocol cohort at Day 0, which included all evaluable subjects for whom at least one assay results was available for the blood samples collected at Day 0.</population>
          <units>EU/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="15"/>
                <count group_id="O4" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.4" lower_limit="8.9" upper_limit="12.1"/>
                    <measurement group_id="O2" value="9.3" lower_limit="8.5" upper_limit="10.0"/>
                    <measurement group_id="O3" value="9.9" lower_limit="8.4" upper_limit="11.7"/>
                    <measurement group_id="O4" value="8.9" lower_limit="8.9" upper_limit="8.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Concentrations for Serum Protein-D Enzymatic Inhibition</title>
        <description>Concentrations are presented as geometric mean concentrations (GMCs). The reference seropositivity cut-off value was ≥ 17.8%.</description>
        <time_frame>At Month 6</time_frame>
        <population>The analysis was performed on the According-to-Protocol cohort at Month 6, which included all evaluable subjects for whom at least one assay results was available for the blood samples collected at Month 6.</population>
        <group_list>
          <group group_id="O1">
            <title>FeCOPD Group</title>
            <description>COPD subjects with ≥ two exacerbations within 365 days prior to the screening visit (frequent exacerbators), aged between 45-75 years</description>
          </group>
          <group group_id="O2">
            <title>NFeCOPD Group</title>
            <description>COPD patients with one exacerbation within 365 days prior to the screening visit (non-frequent exacerbators), aged between 45-75 years</description>
          </group>
        </group_list>
        <measure>
          <title>Concentrations for Serum Protein-D Enzymatic Inhibition</title>
          <description>Concentrations are presented as geometric mean concentrations (GMCs). The reference seropositivity cut-off value was ≥ 17.8%.</description>
          <population>The analysis was performed on the According-to-Protocol cohort at Month 6, which included all evaluable subjects for whom at least one assay results was available for the blood samples collected at Month 6.</population>
          <units>EU/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.4" lower_limit="8.4" upper_limit="10.4"/>
                    <measurement group_id="O2" value="8.9" lower_limit="8.9" upper_limit="8.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects With PD Enzymatic Inhibition Concentration Greater Than or Equal to (≥) 17.8%</title>
        <description>Concentrations were expressed as geometric mean concentrations (GMCs)</description>
        <time_frame>At Day 0</time_frame>
        <population>The analysis was performed on the According-to-Protocol cohort at Day 0, which included all evaluable subjects for whom at least one assay results was available for the blood samples collected at Day 0.</population>
        <group_list>
          <group group_id="O1">
            <title>HNS Group</title>
            <description>Healthy non-smokers aged between 45-75 years</description>
          </group>
          <group group_id="O2">
            <title>HS Group</title>
            <description>Healthy smokers aged between 45-75 years</description>
          </group>
          <group group_id="O3">
            <title>FeCOPD Group</title>
            <description>COPD subjects with ≥ two exacerbations within 365 days prior to the screening visit (frequent exacerbators), aged between 45-75 years</description>
          </group>
          <group group_id="O4">
            <title>NFeCOPD Group</title>
            <description>COPD patients with one exacerbation within 365 days prior to the screening visit (non-frequent exacerbators), aged between 45-75 years</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With PD Enzymatic Inhibition Concentration Greater Than or Equal to (≥) 17.8%</title>
          <description>Concentrations were expressed as geometric mean concentrations (GMCs)</description>
          <population>The analysis was performed on the According-to-Protocol cohort at Day 0, which included all evaluable subjects for whom at least one assay results was available for the blood samples collected at Day 0.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="15"/>
                <count group_id="O4" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects With PD Enzymatic Inhibition Concentration Greater Than or Equal to (≥) 17.8%</title>
        <description>Concentrations were expressed as geometric mean concentrations (GMCs)</description>
        <time_frame>At Month 6</time_frame>
        <population>The analysis was performed on the According-to-Protocol cohort at Month 6, which included all evaluable subjects for whom at least one assay results was available for the blood samples collected at Month 6.</population>
        <group_list>
          <group group_id="O1">
            <title>FeCOPD Group</title>
            <description>COPD subjects with ≥ two exacerbations within 365 days prior to the screening visit (frequent exacerbators), aged between 45-75 years</description>
          </group>
          <group group_id="O2">
            <title>NFeCOPD Group</title>
            <description>COPD patients with one exacerbation within 365 days prior to the screening visit (non-frequent exacerbators), aged between 45-75 years</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With PD Enzymatic Inhibition Concentration Greater Than or Equal to (≥) 17.8%</title>
          <description>Concentrations were expressed as geometric mean concentrations (GMCs)</description>
          <population>The analysis was performed on the According-to-Protocol cohort at Month 6, which included all evaluable subjects for whom at least one assay results was available for the blood samples collected at Month 6.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Frequency of Specific Cluster of Differentiation 4+ (CD4+) T Cells Expressing at Least 2 Markers Among CD 40 Ligand (CD40L), Interleukin 2 (IL-2), Tumor Necrosis Factor-α (TNF-α), Interferon-γ (IFN-γ), IL-13 and IL-17 Upon in Vitro Stimulation</title>
        <time_frame>At Day 0</time_frame>
        <population>The analysis was performed on the According-to-Protocol cohort at Day 0, which included all evaluable subjects for whom at least one assay results was available for the blood samples collected at Day 0.</population>
        <group_list>
          <group group_id="O1">
            <title>HNS Group</title>
            <description>Healthy non-smokers aged between 45-75 years</description>
          </group>
          <group group_id="O2">
            <title>HS Group</title>
            <description>Healthy smokers aged between 45-75 years</description>
          </group>
          <group group_id="O3">
            <title>FeCOPD Group</title>
            <description>COPD subjects with ≥ two exacerbations within 365 days prior to the screening visit (frequent exacerbators), aged between 45-75 years</description>
          </group>
          <group group_id="O4">
            <title>NFeCOPD Group</title>
            <description>COPD patients with one exacerbation within 365 days prior to the screening visit (non-frequent exacerbators), aged between 45-75 years</description>
          </group>
        </group_list>
        <measure>
          <title>Frequency of Specific Cluster of Differentiation 4+ (CD4+) T Cells Expressing at Least 2 Markers Among CD 40 Ligand (CD40L), Interleukin 2 (IL-2), Tumor Necrosis Factor-α (TNF-α), Interferon-γ (IFN-γ), IL-13 and IL-17 Upon in Vitro Stimulation</title>
          <population>The analysis was performed on the According-to-Protocol cohort at Day 0, which included all evaluable subjects for whom at least one assay results was available for the blood samples collected at Day 0.</population>
          <units>T cells/million cells</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="15"/>
                <count group_id="O4" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="159.6" spread="67.29"/>
                    <measurement group_id="O2" value="163.5" spread="87.11"/>
                    <measurement group_id="O3" value="173.9" spread="89.69"/>
                    <measurement group_id="O4" value="170.1" spread="88.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Frequency of Specific Cluster of Differentiation 8+ (CD8+) T Cells Expressing at Least 2 Markers Among CD 40 Ligand (CD40L), Interleukin 2 (IL-2), Tumor Necrosis Factor-α (TNF-α), Interferon-γ (IFN-γ), IL-13 and IL-17 Upon in Vitro Stimulation</title>
        <time_frame>At Day 0</time_frame>
        <population>The analysis was performed on the According-to-Protocol cohort at Day 0, which included all evaluable subjects for whom at least one assay results was available for the blood samples collected at Day 0.</population>
        <group_list>
          <group group_id="O1">
            <title>HNS Group</title>
            <description>Healthy non-smokers aged between 45-75 years</description>
          </group>
          <group group_id="O2">
            <title>HS Group</title>
            <description>Healthy smokers aged between 45-75 years</description>
          </group>
          <group group_id="O3">
            <title>FeCOPD Group</title>
            <description>COPD subjects with ≥ two exacerbations within 365 days prior to the screening visit (frequent exacerbators), aged between 45-75 years</description>
          </group>
          <group group_id="O4">
            <title>NFeCOPD Group</title>
            <description>COPD patients with one exacerbation within 365 days prior to the screening visit (non-frequent exacerbators), aged between 45-75 years</description>
          </group>
        </group_list>
        <measure>
          <title>Frequency of Specific Cluster of Differentiation 8+ (CD8+) T Cells Expressing at Least 2 Markers Among CD 40 Ligand (CD40L), Interleukin 2 (IL-2), Tumor Necrosis Factor-α (TNF-α), Interferon-γ (IFN-γ), IL-13 and IL-17 Upon in Vitro Stimulation</title>
          <population>The analysis was performed on the According-to-Protocol cohort at Day 0, which included all evaluable subjects for whom at least one assay results was available for the blood samples collected at Day 0.</population>
          <units>T cells/million cells</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="15"/>
                <count group_id="O4" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.9" spread="56.74"/>
                    <measurement group_id="O2" value="125.2" spread="73.93"/>
                    <measurement group_id="O3" value="125.2" spread="44.12"/>
                    <measurement group_id="O4" value="161.3" spread="43.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Positive Sputum - Culture Testing Results</title>
        <time_frame>At Day 0</time_frame>
        <population>The analysis was performed on the According-to-Protocol cohort at Day 0, which included all evaluable subjects for whom at least one assay results was available for the blood samples collected at Day 0.</population>
        <group_list>
          <group group_id="O1">
            <title>FeCOPD Group</title>
            <description>COPD subjects with ≥ two exacerbations within 365 days prior to the screening visit (frequent exacerbators), aged between 45-75 years</description>
          </group>
          <group group_id="O2">
            <title>NFeCOPD Group</title>
            <description>COPD patients with one exacerbation within 365 days prior to the screening visit (non-frequent exacerbators), aged between 45-75 years</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Positive Sputum - Culture Testing Results</title>
          <population>The analysis was performed on the According-to-Protocol cohort at Day 0, which included all evaluable subjects for whom at least one assay results was available for the blood samples collected at Day 0.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any bacteria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Streptococcus pneumoniae</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Haemophilus influenzae</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moraxella catarrhalis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Staphylococcus aureus</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pseudomonas aeruginosa</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other bacteria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Positive Nasopharyngeal Swab - Culture Testing Results</title>
        <time_frame>At Day 0</time_frame>
        <population>The analysis was performed on the According-to-Protocol cohort at Day 0, which included all evaluable subjects for whom at least one assay results was available for the blood samples collected at Day 0.</population>
        <group_list>
          <group group_id="O1">
            <title>HNS Group</title>
            <description>Healthy non-smokers aged between 45-75 years</description>
          </group>
          <group group_id="O2">
            <title>HS Group</title>
            <description>Healthy smokers aged between 45-75 years</description>
          </group>
          <group group_id="O3">
            <title>FeCOPD Group</title>
            <description>COPD subjects with ≥ two exacerbations within 365 days prior to the screening visit (frequent exacerbators), aged between 45-75 years</description>
          </group>
          <group group_id="O4">
            <title>NFeCOPD Group</title>
            <description>COPD patients with one exacerbation within 365 days prior to the screening visit (non-frequent exacerbators), aged between 45-75 years</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Positive Nasopharyngeal Swab - Culture Testing Results</title>
          <population>The analysis was performed on the According-to-Protocol cohort at Day 0, which included all evaluable subjects for whom at least one assay results was available for the blood samples collected at Day 0.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="15"/>
                <count group_id="O4" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any bacteria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Streptococcus pneumoniae</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Haemophilus influenzae</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moxarella catarrhalis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Staphylococcus aureus</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pseudomonas aeruginosa</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other bacteria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Positive Oropharyngeal Swab - Culture Testing Results</title>
        <time_frame>At Day 0</time_frame>
        <population>The analysis was performed on the According-to-Protocol cohort at Day 0, which included all evaluable subjects for whom at least one assay results was available for the blood samples collected at Day 0.</population>
        <group_list>
          <group group_id="O1">
            <title>HNS Group</title>
            <description>Healthy non-smokers aged between 45-75 years</description>
          </group>
          <group group_id="O2">
            <title>HS Group</title>
            <description>Healthy smokers aged between 45-75 years</description>
          </group>
          <group group_id="O3">
            <title>FeCOPD Group</title>
            <description>COPD subjects with ≥ two exacerbations within 365 days prior to the screening visit (frequent exacerbators), aged between 45-75 years</description>
          </group>
          <group group_id="O4">
            <title>NFeCOPD Group</title>
            <description>COPD patients with one exacerbation within 365 days prior to the screening visit (non-frequent exacerbators), aged between 45-75 years</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Positive Oropharyngeal Swab - Culture Testing Results</title>
          <population>The analysis was performed on the According-to-Protocol cohort at Day 0, which included all evaluable subjects for whom at least one assay results was available for the blood samples collected at Day 0.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="15"/>
                <count group_id="O4" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any bacteria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Streptococcus pneumoniae</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Haemophilus influenzae</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moxarella catarrhalis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Staphylococcus aureus</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pseudomonas aeruginosa</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other bacteria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Serious Adverse Events (SAEs) up to Month 6.</time_frame>
      <desc>Non-serious/frequent adverse events were not collected in this study.</desc>
      <group_list>
        <group group_id="E1">
          <title>HNS Group</title>
          <description>Healthy non-smokers aged between 45-75 years</description>
        </group>
        <group group_id="E2">
          <title>HS Group</title>
          <description>Healthy smokers aged between 45-75 years</description>
        </group>
        <group group_id="E3">
          <title>FeCOPD Group</title>
          <description>COPD subjects with ≥ two exacerbations within 365 days prior to the screening visit (frequent exacerbators), aged between 45-75 years</description>
        </group>
        <group group_id="E4">
          <title>NFeCOPD Group</title>
          <description>COPD patients with one exacerbation within 365 days prior to the screening visit (non-frequent exacerbators), aged between 45-75 years</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 15.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Bronchospasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>GSK Response Center</name_or_title>
      <organization>GlaxoSmithKline</organization>
      <phone>866-435-7343</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

